Clinical Trials Sponsored by UCB, Inc

Total 36147 results

UCB BIOSCIENCES, Inc.

Recruiting

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome (ORCHID)

Dravet Syndrome

United States
UCB BIOSCIENCES, Inc.

Completed

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures (VALUE)

Epilepsy

United States, Australia, Brazil, Bulgaria, China, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Taiwan
UCB BIOSCIENCES, Inc.

Completed

Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children. (ASPIRE)

Epilepsy

United States, Hungary, Italy, Poland, Ukraine
UCB BIOSCIENCES, Inc.

Completed

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy (BRITE™)

Epilepsy

Czechia, Germany, Poland, Austria, Belgium, Brazil, Canada, Estonia, Finland, France, Hong Kong, Hungary, India, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, Puerto Rico, Russian Federation, Spain, Sweden, T... and more
UCB BIOSCIENCES, Inc.

Completed

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures

Epilepsy With Partial-onset Seizures

United States, Argentina, Brazil, Bulgaria, China, Croatia, Czechia, France, Georgia, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Se... and more
UCB BIOSCIENCES, Inc.

Completed

Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

Epilepsy

United States
UCB BIOSCIENCES, Inc.

Completed

SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry (SECURE)

Crohn's Disease

United States
UCB BIOSCIENCES, Inc.

Completed

An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy

Epilepsy

United States, Belgium, China, France, Germany, Hungary, Italy, Japan, Mexico, Poland, Ukraine
UCB BIOSCIENCES, Inc.

Completed

Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures (ALEX-MT)

Epilepsy

Austria, United States, Australia, Canada, Denmark, France, Germany, Ireland, Italy, Poland, Puerto Rico, Spain, United Kingdom
UCB BIOSCIENCES, Inc.

Completed

Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

Partial Epilepsies

United States
UCB BIOSCIENCES, Inc.

Completed

Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures

Partial Epilepsies | Partial Onset Seizures

United States
UCB BIOSCIENCES, Inc.

Completed

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

Restless Legs Syndrome

United States
UCB BIOSCIENCES, Inc.

Completed

Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy

Epilepsy

United States
UCB BIOSCIENCES, Inc.

Completed

Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

Partial Epilepsies | Partial Onset Seizures

United States
UCB BIOSCIENCES, Inc.

Completed

Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

Epilepsy

United States
UCB BIOSCIENCES, Inc.

Completed

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

Restless Legs Syndrome

United States
UCB BIOSCIENCES, Inc.
UCB Biopharma SRL

Completed

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

Epilepsy

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, China, Colombia, Croatia, Czechia, Estonia, France, Georgia, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Monten... and more
UCB BIOSCIENCES, Inc.
Zogenix, Inc.

Active, not recruiting

An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency (Continuation)

Thymidine Kinase 2 Deficiency

United States, Israel, Spain
UCB BIOSCIENCES, Inc.
Parexel

Completed

Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects

Healthy

United States
UCB PHARMA Inc. (US)

Completed

This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

Epilepsy

United States, Australia, Brazil, Canada, India, Mexico
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

Rheumatoid Arthritis

United States, Belgium, United Kingdom
UCB BIOSCIENCES, Inc.
PPD; Parexel

Completed

A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers (CRADLE)

Rheumatoid Arthritis | Crohn's Disease | Psoriatic Arthritis | Ankylosing Spondylitis | Axial Spondyloarthritis (AxSpA) | Non-radiographic Evidence-AxSpA

United States, Netherlands, Switzerland
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Japan, Korea, Republic of, Taiwan
UCB BIOSCIENCES, Inc.
PPD; Parexel

Completed

A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta (CRIB)

Rheumatoid Arthritis | Crohn's Disease | Psoriatic Arthritis | Ankylosing Spondylitis | Axial Spondyloarthritis (AxSpA) | Non-radiographic Evidence-AxSpA

Netherlands, Switzerland, United States, France
Zogenix, Inc.

Completed

A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)

Healthy
Zogenix, Inc.

Completed

Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain

Chronic Pain

United States
Zogenix, Inc.

Recruiting

A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder

Generalized Tonic Clonic Seizure | CDKL5 Deficiency Disorder | Epileptic Spasm | Refractory Seizures

United States, Japan, Germany, Netherlands, Portugal, Spain, Belgium, United Kingdom, Austria, Georgia, Israel, Ireland
Zogenix, Inc.

Completed

A Study on the Effects of Repeat Doses of Intraject® Sumatriptan on Local Site Signs

Healthy
Zogenix, Inc.

Completed

Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment

Renal Impairment
Zogenix, Inc.

Completed

To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release Capsules

Healthy
Zogenix, Inc.

Completed

A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery

Postoperative Pain
Zogenix, Inc.

Completed

Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment

Hepatic Impairment
Zogenix, Inc.

Completed

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
UCB BIOSCIENCES, Inc.
PRA Health Sciences

Terminated

Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures

Nonconvulsive Electrographic Seizures

United States
UCB BIOSCIENCES, Inc.
Syneos Health; Parexel

Terminated

UCB Cimzia Pregnancy Follow-up Study

Rheumatoid Arthritis (RA) | Crohn's Disease (CD) | Psoriatic Arthritis (PsA) | Axial Spondyloarthritis and Ankylosing Spondylitis

United States
Zogenix, Inc.

Approved for marketing

ZX008 Expanded Access Protocol

Dravet Syndrome
Zogenix, Inc.

Completed

Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain

Back Pain Lower Back Chronic

United States
Zogenix, Inc.

Completed

A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack

Migraine Headache

United States
Zogenix, Inc.

Completed

A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia

Schizophrenia

United States
Zogenix, Inc.

Completed

A Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System

Pharmacokinetics | Bioequivalence

United States
Zogenix, Inc.

Completed

A Study on the Intraject Instructions for Use

Healthy
Zogenix, Inc.

Completed

A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain

Osteoarthrosis
UCB BIOSCIENCES, Inc.
Pharmaceutical Research Associates

Completed

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications (VALOR)

Epilepsy

United States, Australia, Belgium, Brazil, Bulgaria, China, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Taiwan
UCB Pharma SA
ReSearch Pharmaceutical Services, Inc.

Completed

Health-related Quality of Life and Patient-reported Outcomes in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol (SONAR-12)

Rheumatoid Arthritis

Spain
Ra Pharmaceuticals, Inc.

Active, not recruiting

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)

Generalized Myasthenia Gravis

United States, Canada, France, Germany, Italy, Japan, Norway, Poland, Spain, United Kingdom
Ra Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE)

Myasthenia Gravis, Generalized

United States, Canada, France, Germany, Italy, Japan, Norway, Poland, Spain, United Kingdom
UCB Celltech

Terminated

The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents (NURTURE)

Crohn's Disease

United States, Canada, New Zealand, Australia
UCB Celltech

Completed

A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis

Mild to Moderate Psoriasis

United Kingdom
Ra Pharmaceuticals, Inc.

Terminated

Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Australia, Canada, Finland, Germany, Hungary, New Zealand, United Kingdom
Zogenix MDS, Inc.

Completed

A RETROspective Study of Patients With TK2d (RETRO)

Thymidine Kinase 2 (TK2)

United States, Spain, Israel

Clinical Trials Sponsored by UCB, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations